MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial metrics, optimistic guidance, and strategic growth initiatives. The company expects significant growth in Afrezza sales and FUROSCIX, supported by investments in sales force expansion and new product developments. The strategic financing with Blackstone provides a substantial non-dilutive funding boost. Market opportunities, especially in the NTM market, are promising, and the company is confident in its pricing model. Despite some unclear management responses, the overall sentiment is positive, with potential catalysts like the Afrezza label update and ReadyFlow injector expansion.
Key Financial Performance
Total Revenue $82 million in Q3 2025, a 17% increase year-over-year, driven primarily by royalties earned on Tyvaso DPI.
Tyvaso DPI Royalties $33 million in Q3 2025, a 23% increase year-over-year, reflecting strong performance under collaboration with United Therapeutics.
Collaboration and Services Revenue $27 million in Q3 2025, up 14% year-over-year, primarily from manufacturing revenue and deferred revenue recognition.
Afrezza Net Revenue $18.5 million in Q3 2025, a 23% increase year-over-year, driven by a 31% growth in new prescriptions and 27% growth in total prescriptions, despite a 15% decline in units per script due to a focus on type 1 diabetes.
VGo Revenue $3.8 million in Q3 2025, a 19% decrease year-over-year, consistent with the company's decision to no longer actively promote the product.
FUROSCIX Revenue $19.3 million in Q3 2025, with year-to-date revenue reaching $47.1 million, a 95% increase year-over-year, driven by expanded sales force and increased prescribing adoption.
GAAP Net Income $8 million in Q3 2025, compared to $11.6 million in Q3 2024, reflecting acquisition-related expenses and investments in growth.
Non-GAAP Net Income $22.4 million in Q3 2025, up from $15.4 million in Q3 2024, reflecting strong operational performance despite significant investments in future growth.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Afrezza supplemental BLA: Accepted for review with a PDUFA date of Q2 2026. If approved, it will be the first new insulin for pediatric patients in over 100 years.
FUROSCIX auto-injector: sNDA submitted to the FDA in Q3 with an expected PDUFA date of Q3 2026. This device aims to simplify admissions, expand treatment options, and reduce costs.
Tyvaso DPI: Generated $59 million in royalty and manufacturing-led revenue in Q3. Developed an 80-microgram cartridge to improve patient convenience.
Bumetanid DPI (MNKD-701): Advanced into preclinical development for fluid overload in CKD and heart failure.
scPharmaceuticals acquisition: Acquisition completed, adding FUROSCIX to MannKind's portfolio and expanding into cardiorenal medicine.
Heart failure and CKD market: Large unmet need with 2.1 million addressable heart failure episodes in the U.S. FUROSCIX targets this market by reducing hospital admissions and readmissions.
Tyvaso DPI label expansion: Potential to expand label to include IPF and/or PPF contingent upon FDA approval.
Revenue growth: Achieved record revenue of $82 million in Q3 2025, a 17% increase year-over-year.
FUROSCIX sales: 27,000 doses dispensed in Q3, up 153% year-over-year. Revenue reached $19.3 million in Q3.
Afrezza sales: Net revenue grew 23% in Q3 2025 compared to Q3 2024. New prescriptions grew 31% year-over-year.
Expansion into pediatrics: Enhanced messaging and expanded field force to target top 50 pediatric centers for Afrezza.
CMS ambulatory specialty model: Aligning FUROSCIX strategy with CMS's new risk-based payment model for heart failure care starting in January 2027.
Collaboration with United Therapeutics: Expanded collaboration to include a second investigational molecule using MannKind's Technosphere technology.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory hurdles: The company faces regulatory risks with multiple submissions to the FDA, including the sNDA for FUROSCIX auto-injector and Afrezza sBLA for pediatric use. Delays or rejections could impact product launches and revenue growth.
Supply chain and manufacturing challenges: The company relies heavily on manufacturing partnerships, such as with United Therapeutics for Tyvaso DPI. Any disruptions in manufacturing or supply chain could adversely affect revenue and product availability.
Financial risks: The company has taken on significant financial commitments, including a $325 million term loan facility with Blackstone and the $133 million acquisition of scPharmaceuticals. These financial obligations could strain cash flow and limit flexibility.
Market competition: The company operates in highly competitive markets, including diabetes care and cardiometabolic medicine. Competitors with more resources or established products could limit market share growth.
Strategic execution risks: The integration of scPharmaceuticals and the expansion of the sales force for FUROSCIX require significant operational focus. Any missteps could delay growth and impact financial performance.
Economic uncertainties: Broader economic conditions, including Medicare spending changes and CMS's new risk-based payment model, could impact the adoption of FUROSCIX and other products.
Clinical trial risks: The company is heavily reliant on the success of its clinical trials, such as the ICoN-1 Phase III study and INFLO Phase II study. Delays or failures in these trials could hinder pipeline progress and future revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Afrezza Pediatric Indication: Afrezza's supplemental BLA was accepted for review with a PDUFA date of Q2 2026. If approved, it will be the first new insulin for pediatric patients in over 100 years. The company is initiating the 'Inhaled First' study to position Afrezza as the first-choice bolus insulin for youth aged 10 to 18 newly diagnosed with type 1 diabetes. This study will evaluate safety and efficacy across 10 leading sites.
FUROSCIX Auto-Injector: The sNDA for FUROSCIX auto-injector was submitted to the FDA in Q3 2025, with an expected PDUFA date of Q3 2026. If approved, this device will simplify admissions, expand treatment options, and reduce costs, enabling reinvestment in growth and margin improvement.
Tyvaso DPI Expansion: Following positive TETON-2 data, United Therapeutics plans to pursue a DPI bridging study in IPF, potentially expanding the Tyvaso DPI label to include IPF and/or PPF, contingent upon FDA approval.
ICoN-1 NTM Phase III Trial: Enrollment for the ICoN-1 NTM Phase III trial was completed ahead of schedule, with trial sizing confirmation expected mid-2026. The market for this indication is expected to exceed $1 billion by the end of the decade.
INFLO Phase II Study (MNKD-201): The INFLO Phase II study for Nintedanib DPI is set to begin enrolling patients in Q1 2026. This trial will evaluate safety, tolerability, and efficacy in 210 patients with IPF over 12 weeks, followed by a 6-month open-label extension.
Bumetanid DPI (MNKD-701): Advancing bumetanid DPI into preclinical development as a non-invasive solution for fluid overload in CKD and heart failure. This formulation aims to provide rapid, portable treatment options.
FUROSCIX Commercial Strategy: Post-acquisition, the focus is on expanding FUROSCIX's role in reducing hospital readmissions for heart failure and CKD patients. The strategy includes targeting post-discharge periods and aligning with CMS's new risk-based payment model starting January 2027.
Revenue Growth Projections: With the addition of FUROSCIX and continued growth in Tyvaso DPI royalties, the company anticipates significant revenue growth. Pro forma commercial product sales would represent 39% of total revenues year-to-date if FUROSCIX were included.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you share any thoughts on the recent approvals from FUROSCIX competitors?
A:The CEO mentioned that they were aware of the competitors during due diligence and felt their product differentiation stood on its merits. They believe their platform has IV-like responses and good bioavailability, which allows for a fast onset of diuresis. They are confident in competing with new market entrants and believe the market will grow with more options and noise.
Q:Can you contextualize the pricing differences and how that funnels down to out-of-pocket costs for patients?
A:The CEO stated that the pricing of the product is not the biggest barrier in Medicare, as the out-of-pocket cost and deductible remain the same regardless of the product's price. The real issue is reimbursement support and smoothing. They feel confident in their pricing model and system for managing patient access and refills.
Q:When do you think we'll start to see a bigger inflection in FUROSCIX growth from your initiatives?
A:The CEO expects to see an impact within six months of their investment decisions, with significant growth starting in Q3 and Q4. They aim to expand the share of voice among cardiologists and nephrologists, with a focus on minimizing disruption to customer relationships.
Q:For the Tyvaso bridging study in IPF, what can you tell us about the timing and design?
A:The CEO mentioned that the study could be a BreezE-eng study and that they expect the company to move quickly to the FDA for clarification and discussion.
Q:Can you comment on the integration process of the scPharma acquisition and the field force composition?
A:The CEO stated that the integration is going smoothly, with cultural alignment between the companies. They have already placed some scPharma employees in key positions and plan to fully integrate by 2026. Sales remain strong, and they are phasing in changes smartly to avoid unnecessary costs.
Q:How do you balance investing in Afrezza and Peds, FUROSCIX, deleveraging the balance sheet, and maintaining operational profitability?
A:The CEO emphasized prioritizing growth investments, particularly in Afrezza Peds and FUROSCIX, while ensuring sustainability. The CFO added that they are addressing a $36 million debt due in 2026 and are focused on maintaining operational profitability.
Q:What is the peak sales opportunity for FUROSCIX, and what do you attribute to the faster pace of enrollment in NTM?
A:The CEO referenced analyst reports estimating FUROSCIX's peak sales at $500 million-plus. For NTM, they attributed faster enrollment to increased awareness among KOLs and recent FDA adjustments to screening criteria. The study is 90% powered, with an interim analysis planned.
Q:What are the potential outcomes for the interim readout of the NTM study?
A:The CEO outlined potential outcomes, including increasing the sample size, ensuring safety database adequacy, futility, or being on track to meet the 180-patient requirement. Japan requires 180 patients, and the U.S. is evaluating the total safety database.
Q:Will there be ongoing sales force expansion for scPharma, and how will it impact SG&A?
A:The CEO confirmed plans for sales force expansion to increase share of voice, particularly among cardiologists. The CFO noted that most commercial costs will remain consistent, with additional investments in key account managers.
Q:Do you expect Afrezza sales to catch up with TRx trends?
A:The CEO expects Q4 to be strong, with refills driving growth. They anticipate TRx trends to stabilize within six months, aligning sales with volume per script.
Q:What is the potential tailwind from the Afrezza conversion dose label update?
A:The CEO stated that the label update will address dosing issues, improving patient retention and satisfaction. This will support sales force expansion and better outcomes for new prescribers.
Q:What is the development path for Nintedanib DPI?
A:The CEO explained that the development path involves short tox studies, straightforward PK studies, and flexibility in dosing. They aim to formulate the product quickly and align with the FDA.
Q:What is the probability of success for the SCP-111 sNDA submission?
A:The CEO reported no red flags from the FDA so far, with inquiries being minor and reasonable. They are optimistic about the submission's progress.
Q:What impact could the ReadyFlow injector have on prescribers and margins?
A:The CEO believes the ReadyFlow injector could expand the market by appealing to new patient segments, such as nursing homes and elderly patients. They see it as a growth driver rather than a replacement for existing products.
Q:Review of Unclear Management Responses
A:The CEO avoided providing specific timelines or detailed guidance for the Tyvaso bridging study in IPF, the exact sales force expansion plans for scPharma, and the precise peak sales trajectory for Afrezza Peds. Additionally, they did not elaborate on the exact financial impact of the SCP-111 sNDA submission or the ReadyFlow injector on margins.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CKD heart
CMS
Co
Division HC
Division Mizuho
Division Oppenheimer
FUROSCIX product
Inc Research
LLC Research
MNKD
Research Division
Securities
VGo
account manager
acquisition scPharmaceuticals
adoption
care
collaboration United
cost
date period
heart failure
hospital admission
hospitalization
overload
potential
prescribing
product sale
provider
readmission
royalty Tyvaso
side
term
transaction
MNKD Transcript
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call presents mixed signals. While there is positive growth in FUROSCIX sales and strategic product launches, declines in Tyvaso DPI revenues and GAAP net losses are concerning. The Q&A reveals positive sentiment towards FUROSCIX and Afrezza growth but lacks clarity on some strategic initiatives. The market cap suggests moderate volatility, and the combination of optimistic guidance with some financial setbacks results in a neutral prediction for stock movement.
MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary highlights strong financial performance, with significant revenue growth driven by Afrezza and FUROSCIX. Product development is advancing, with promising pipeline updates and strategic initiatives. Market strategy and shareholder return plans are not explicitly detailed but implied through growth projections. The Q&A session reveals optimism for future revenue growth, particularly with the pediatric segment and FUROSCIX auto-injector launch. Despite some management vagueness, the overall sentiment is positive, with potential catalysts for stock price appreciation. Considering the small-cap nature, a positive stock price movement (2% to 8%) is expected.
MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call highlights strong financial metrics, optimistic guidance, and strategic growth initiatives. The company expects significant growth in Afrezza sales and FUROSCIX, supported by investments in sales force expansion and new product developments. The strategic financing with Blackstone provides a substantial non-dilutive funding boost. Market opportunities, especially in the NTM market, are promising, and the company is confident in its pricing model. Despite some unclear management responses, the overall sentiment is positive, with potential catalysts like the Afrezza label update and ReadyFlow injector expansion.
MNKD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
